Sudha Biddinger

Sudha Biddinger is a faculty researcher at Harvard Medical School, affiliated with Boston Children's Hospital, where she leads the Biddinger Laboratory. Her work is centered in the Department of Pediatrics within the Faculty of Medicine, focusing on the molecular underpinnings of metabolic diseases.

• Institution: Harvard Medical School
• Hospital Affiliation: Boston Children's Hospital
• Research Unit: Biddinger Laboratory
• Department: Department of Pediatrics
• School: Faculty of Medicine

Dr. Biddinger's research explores the complex relationships between obesity, insulin resistance, and associated metabolic disorders such as nonalcoholic fatty liver disease (MASLD), dyslipidemia, cardiovascular disease, and gallstones. She investigates key regulatory pathways including hepatic insulin signaling, cholesterol and bile acid metabolism, mTORC1 activity, and the impact of gut microbiota-derived metabolites like trimethylamine N-oxide (TMAO). Her work combines molecular biology, genetics, and translational approaches to uncover mechanisms linking metabolic dysfunction to clinical disease.

Analysis of her recent publications reveals a strong focus on lipid metabolism, gene regulation in the liver, and the role of insulin in maintaining metabolic homeostasis. Her studies frequently employ transgenic mouse models and human metabolic data to validate findings. There is a consistent theme of exploring how perturbations in insulin signaling cascade into systemic metabolic disease, with implications for therapeutic intervention in diabetes and cardiovascular conditions.

Dr. Biddinger has published in top-tier journals including Nature, Science, Cell Metabolism, and Circulation, demonstrating significant contributions to the field of metabolic research. Her work bridges basic science and clinical relevance, particularly in pediatric and young adult populations with type 1 and type 2 diabetes.

She mentors research within her laboratory and likely supervises trainees, though specific students are not listed. While no formal awards or grants are mentioned in the provided text, her publication record suggests successful funding and recognition in the research community. Her lab actively investigates novel therapeutic targets such as epsins, CYP7B1, and mTORC1 inhibitors for metabolic diseases.